Visão geral da empresa
A biopharmaceutical enterprise focused on the development, manufacturing, and commercialization of products designed to treat rare cardiopulmonary diseases within the United States market. Liquidia Corporation operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, a classification that signifies its focus on specialized pharmaceutical solutions rather than mass-market commodities. The company maintains a substantial market capitalization of $3.37B, supported by annual revenue of $158.32M and a workforce consisting of 216 employees. These valuation and revenue figures indicate that the market assigns significant worth to the company's pipeline of lead product candidates, including YUTREPIA, despite the current financial challenges typical of early-stage therapeutic development phases.
Saúde financeira
The company reported revenue of $158.32M over the trailing twelve months, yet it posted a net income of -$68.92M and an EBITDA of -$50.35M, revealing a substantial gap between top-line sales and profitability driven by high operational costs associated with drug development and commercialization. This negative free cash flow of -$43.12M suggests that the company is currently burning cash, which limits immediate financial flexibility but is often expected for firms investing heavily in R&D and market expansion. Liquida Corporation demonstrates a gross margin of 91.6%, indicating highly efficient production costs relative to sales, while an operating margin of 21.5% reflects significant overhead expenses that have not yet been fully offset by gross profits. However, the profit margin stands at -43.5%, confirming that the company is operating at a loss on a bottom-line basis due to substantial non-operating expenses or significant investment in future growth initiatives. On the balance sheet, the company holds cash of $190.68M against total debt of $197.93M, resulting in a debt-to-equity ratio of 442.31, which characterizes the entity as highly leveraged with debt exceeding its liquid cash reserves. The current ratio of 2.01 indicates that the company possesses more than twice the current assets required to cover its short-term liabilities, suggesting a manageable level of short-term liquidity despite the high debt load. Furthermore, the return on equity is -111.1% and the return on assets is -11.5%, metrics that reveal that management is currently unable to generate positive returns on the capital invested by shareholders or the assets utilized in operations.
Avaliação de valorização
Valuation metrics for Liquidia Corporation present a complex picture, with a trailing P/E ratio marked as N/A due to negative earnings, while the forward P/E is listed at 7.29, implying that the market expects a significant turnaround in earnings trajectory over the next twelve months. The price-to-book ratio is extremely high at 74.44, suggesting that the market values the company's equity at a massive premium relative to its net asset value, likely reflecting confidence in the potential value of its intangible assets and drug pipeline. Alternative valuation measures include a price-to-sales ratio of 21.25 and an EV/EBITDA of -66.98, which further underscores the difficulty in applying traditional multiples to a company currently generating losses and indicates a valuation based primarily on future growth expectations rather than current cash generation. Regarding price action, the stock has traded between a 52-week low of $11.26 and a high of $46.67, and without a specific current share price provided in the facts, the relative position to this range cannot be mathematically calculated, though the wide spread indicates high volatility. The beta of 0.46 suggests that the stock's price volatility is significantly lower than the broader market, moving roughly half as much as the market index during periods of standard volatility.
Growth & Income
Revenue growth year-over-year is an extraordinary 3054.6%, driven by likely initial sales of a new product launch or a one-time event, whereas earnings growth is N/A, indicating that profitability has not yet improved at a pace comparable to the revenue expansion. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, meaning the financial strategy prioritizes retaining earnings to fund research, development, and commercialization efforts rather than returning capital to shareholders. This reinvestment approach is typical for biopharmaceutical companies in the specialty and generic drug sector that are still navigating the path to profitability. The overall growth and income profile is characterized by explosive top-line revenue expansion coupled with continued losses and a lack of dividend income, creating a high-risk, high-reward financial environment dependent on future regulatory approvals and commercial success.